Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: A randomized, placebo controlled and active-controlled study

International Clinical Psychopharmacology

Volumn 27, Issue 1, 2012, Pages 40-54

  Merideth, Charles ^a   Cutler, Andrew J ^b   She, Fahua ^c   Eriksson, Hans ^d  

^a Affiliated Research Institute Inc   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

atypical antipsychotic; extended release; generalized anxiety disorder; phase III; placebo controlled; quetiapine XR; randomized

Indexed keywords

ESCITALOPRAM; PLACEBO; QUETIAPINE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HERPES ESOPHAGITIS; HUMAN; HYPERLIPIDEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREMOR; VOMITING; XEROSTOMIA;

ACUTE DISEASE; ADULT; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLACEBOS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 83055184288     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834d9f49     Document Type: Article

References (42)

1. Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, et al. (2004). Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161:1642-1649. (Pubitemid 39201462)
2. Baldwin DS, Nair RV (2005). Escitalopram in the treatment of generalized anxiety disorder. Expert Rev Neurother 5:443-449. (Pubitemid 41021050)
3. Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW (2005). Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: A double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 66:94-99.
4. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, et al. (2001). Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 62 (Suppl 11):53-58. (Pubitemid 32537578)
5. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ (2008). World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders-First Revision. World J Biol Psychiatry 9:248-312.
6. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, et al. (2010). Extended-release quetiapine fumarate (quetiapine XR): A once-daily mono-therapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study. Int J Neuropsychophar-macol 13:305-320.
7. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676. (Pubitemid 19154942)
8. Barnes TR (2003). The Barnes Akathisia Rating Scale-revisited. J Psychophar-macol 17:365-370.
9. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 28:193-213. (Pubitemid 19144991)
10. Canadian Psychiatric Association (2006). Management of anxiety disorders. Can J Psychiatry 51 (Suppl 2):1S-93S.
11. Chouinard G (2004). Issues in the clinical use of benzodiazepines: Potency, withdrawal, and rebound. J Clin Psychiatry 65 (Suppl 5):7-12.
12. Clayton AH, McGarvey EL, Clavet GJ (1997). The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity. Psychopharma-col Bull 33:731-745. (Pubitemid 28128129)
13. Cutler AJ (2003). Sexual dysfunction and antipsychotic treatment. Psychoneuro-endocrinology 28:69-82. (Pubitemid 36015662)
14. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo-and duloxetine-controlled study. J Clin Psychiatry 70:526-539.
15. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 29:321-326. (Pubitemid 23311543)
16. Ferguson JM (2001). SSRI antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3:22-27. (Pubitemid 33807486)
17. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D (2008). Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 24:21-32. (Pubitemid 351160235)
18. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283:3082-3088. (Pubitemid 30399718)
19. Gorman JM (2002). Treatment of generalized anxiety disorder. J Clin Psychiatry 63 (Suppl 8):17-23. (Pubitemid 34535253)
20. Gorman JM (2003). Treating generalized anxiety disorder. J Clin Psychiatry 64 (Suppl 2):24-29. (Pubitemid 36231845)
21. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
22. Haslam C, Brown S, Atkinson S, Haslam R (2004). Patients' experiences of medication for anxiety and depression: Effects on working life. Fam Pract 21:204-212. (Pubitemid 38489406)
23. Hoffman DL, Dukes EM, Wittchen HU (2006). Human and economic burden of generalized anxiety disorder. Depress Anxiety 25:72-90.
24. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. (2007). Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:832-842. (Pubitemid 47015481)
25. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H (2011). Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: A long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 26:11-24.
26. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H (2011). A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 31:418-428.
27. Leo RJ (1996). Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449-454. (Pubitemid 26362308)
28. Magi K, Mezhebovsky I, She F, Datto C, Eriksson HA (2009). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) mono-therapy in elderly patients with generalised anxiety disorder (GAD). World J Biol Psychiatry 10:239.
29. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, et al. (2000). Interruption of selective serotonin reuptake inhibitor treatment: Double-blind, placebo-controlled trial. Br J Psychiatry 176:363-368.
30. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
31. National Institutes of Mental Health (1970). CGI: Clinical global impressions. In: Guy W, Bonato RR, editors. Manual for the ECDEU Assessment Battery. Chevy Chase: NIMH. pp. 1-6.
32. Ninan PT (2001). Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry 62 (Suppl 19):5-10. (Pubitemid 32911034)
33. Pinson L, Gray GE (2003). Psychopharmacology: Number needed to treat: An underused measure of treatment effect. Psychiatr Serv 54:145-146, 154.
34. Pollack MH (2001). Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 62 (Suppl 19):20-25. (Pubitemid 32911036)
35. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, et al. (2001). Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:350-357. (Pubitemid 32545557)
36. Rickels K, Downing R, Schweizer E, Hassman H (1993). Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884-895. (Pubitemid 23330980)
37. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry 44:77-87. (Pubitemid 28305526)
38. Rubio G, Lopez-Ibor JJ (2007). Generalized anxiety disorder: A 40-year follow-up study. Acta Psychiatr Scand 115:372-379. (Pubitemid 46570059)
39. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
40. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D (2010). Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 121:106-115.
41. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H (2009). Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study. CNS Spectr 14:299-313.
42. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J (2002). Generalized anxiety and depression in primary care: Prevalence, recognition, and management. J Clin Psychiatry 63 (Suppl 8):24-34. (Pubitemid 34535254)